Analytical Data
-
Gene name
DcR3/TNFRSF6B
- Application
-
Alternative Names
Tumor necrosis factor receptor superfamily member 6B; Decoy receptor 3; TNFRSF6B; DCR3; TR6
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95407
-
Expression Region
V30-H300
-
Molecular Weight
60-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DcR3, also known as TNFRSF6B, is a member of the tumor necrosis factor receptor (TNFR) superfamily, which plays a critical role in regulating immune responses. This decoy receptor can bind to various ligands, such as TRAIL (TNF-related apoptosis-inducing ligand), and prevent them from activating apoptosis in target cells. Its expression has been linked to various pathological conditions, including cancer, where it may contribute to tumor immune evasion by inhibiting apoptosis in tumor cells. The protein's ability to modulate apoptotic signaling pathways makes it a significant focus of research, particularly in understanding how tumors evade immune surveillance. Furthermore, DcR3 levels have been correlated with disease progression in several malignancies, suggesting its potential as a biomarker for cancer prognosis. The study of recombinant DcR3/TNFRSF6B proteins has garnered interest for their therapeutic implications, as modulating its interactions could enhance anti-tumor immunity or provide insights into cancer treatment strategies. By exploring the biochemical properties, signaling mechanisms, and the role of DcR3 in the immune microenvironment, researchers aim to develop novel therapeutic approaches that leverage its unique functions to combat cancer and other diseases linked to dysregulated apoptosis. Overall, the investigation of DcR3/TNFRSF6B not only enhances our understanding of immune regulation in health and disease but also opens avenues for new therapeutic interventions in oncology and beyond.
